Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Daiichi Sankyo Company, Limited
  6. Summary
    4568   JP3475350009

DAIICHI SANKYO COMPANY, LIMITED

(4568)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
07/26/2021 07/27/2021 07/28/2021 07/29/2021 07/30/2021 Date
2256.5 2251 2224.5 2225.5 2159.5 Last
2928000 2439600 2827800 2479900 5248600 Volume
+1.39% -0.24% -1.18% +0.04% -2.97% Change
Estimated financial data (e)
Sales 2022 998 B 9 095 M 9 095 M
Net income 2022 57 913 M 528 M 528 M
Net cash position 2022 625 B 5 699 M 5 699 M
P/E ratio 2022 71,9x
Yield 2022 1,23%
Sales 2023 1 055 B 9 621 M 9 621 M
Net income 2023 79 182 M 722 M 722 M
Net cash position 2023 665 B 6 063 M 6 063 M
P/E ratio 2023 52,6x
Yield 2023 1,33%
Capitalization 4 139 B 37 706 M 37 727 M
EV / Sales 2022 3,52x
EV / Sales 2023 3,29x
Nbr of Employees 16 033
Free-Float 88,1%
More Financials
Company
Daiichi Sankyo Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the United States, Europe and other markets. The Company is also engaged in the research, development,... 
Sector
Pharmaceuticals
Calendar
07/30Earnings Release
More about the company
Ratings of Daiichi Sankyo Company, Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about DAIICHI SANKYO COMPANY, LIMITED
07/30DAIICHI SANKYO : Top Management Presentation
PU
07/30DAIICHI SANKYO : Consolidated Financial Results for the First Three Months of th..
PU
07/30DAIICHI SANKYO : Reference Data
PU
07/21Daiichi Sankyo Completes Issue of Shares in Stock Compensation Program
MT
07/08ASTRAZENECA : Daiichi Sankyo, AstraZeneca's Late-Stage Trial of Enhertu for Gast..
MT
07/08ASTRAZENECA : Daiichi Sankyo Late-Stage Trial of Enhertu for Gastric Cancer Dose..
MT
07/08Daiichi Sankyo Company, Limited and AstraZeneca Announces DESTINY-Gastric04 H..
CI
07/02Nikkei ends higher on Sony, Toyota boost; posts weekly drop on virus woes
RE
07/01TOKYO ELECTRIC POWER INCORPORATED : Olympics-Japan PM says no spectators possibl..
RE
06/23Daiichi Sankyo to Issue Common Stocks to Employees Under Share Compensation P..
MT
06/22DAIICHI SANKYO : Corporate Governance Report
PU
06/15Japan's Daiichi Sankyo halts trials of existing drug for COVID-19 treatment
RE
06/14Japanese shares inch higher, Toshiba up after ouster of board directors
RE
06/13Japanese shares track Wall Street higher, gains capped as investors await Fed..
RE
06/11Daiichi Sankyo Company, Limited Announces New Data for valemetostat
CI
More news
News in other languages on DAIICHI SANKYO COMPANY, LIMITED
07/30MÄRKTE ASIEN/Schwach - Corona-Sorgen in Tokio nehmen zu
07/30MÄRKTE ASIEN/Schwächer - Fanuc und Fujitsu nach Zahlen sehr schwach
07/16Lonza trouve preneur pour des capacités de production à Viège
07/13DAIICHI SANKYO : vers un vaccin japonais ?
07/13PLANÈTE BOURSE : La revue de presse du mardi 13 juillet 2021
More news
Analyst Recommendations on DAIICHI SANKYO COMPANY, LIMITED
More recommendations
Chart DAIICHI SANKYO COMPANY, LIMITED
Duration : Period :
Daiichi Sankyo Company, Limited Technical Analysis Chart | 4568 | JP3475350009 | MarketScreener
Technical analysis trends DAIICHI SANKYO COMPANY, LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 2 159,50 JPY
Average target price 3 572,31 JPY
Spread / Average Target 65,4%
EPS Revisions
Managers and Directors
Sunao Manabe President, CEO & Representative Director
Hiroyuki Okuzawa CFO, Director, Executive Officer & Head-Management
Ken Takeshita Global Director-Research & Development
Noritaka Uji Independent Outside Director
Tsuguya Fukui Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
DAIICHI SANKYO COMPANY, LIMITED-38.91%37 706
JOHNSON & JOHNSON9.42%453 313
ROCHE HOLDING AG13.38%337 105
PFIZER, INC.16.30%239 637
NOVARTIS AG0.28%225 343
ELI LILLY AND COMPANY44.22%221 348